A Multi-Centre Trial Investigating the Long Term Safety and Tolerability of Desmopressin (FE 992026) Orally Disintegrating Tablets for the Treatment of Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Adverse reactions
- Sponsors Ferring Pharmaceuticals
- 14 Sep 2018 Status changed from active, no longer recruiting to completed.
- 09 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2017 New trial record